ENGINEERINGNET.EU -- Q-Biologicals, a Belgian biotech company, announces that it has entered into a service framework agreement with Bayer CropScience to produce and purify recombinant proteins for Bayer. Production of two recombinant proteins has already been commissioned.
Q-Biologicals CEO, Annie Van Broekhoven, comments: “The signing of this service framework agreement is a strong endorsement of the need of service provider like Q-Biologicals in the Flanders (Belgian) region.”
“This collaboration with Bayer is an important step in fulfilling our ambition to become a key player in the field of production of biologicals.”
Q-Biologicals is the former biologicals department of Innogenetics/Fujirebio. It incorporates technology acquired from the Protein Service Facility of the Flanders Institute for Biotechnology and Ghent University.
The company focuses on providing services in the field of process development and manufacturing of recombinant proteins, viruses and live cells.
(picture: Bayer Cropscience)
BACKGROUNDER
The principal technological expertise of Q-Biologicals is the production of recombinant proteins derived from microbial as well as eukaryotic systems, purification of recombinant proteins for research purposes and with pharmaceutical grade quality, including formulation development and stress stability studies.
Q-Biologicals also has an extensive expertise in the manufacturing of viruses and living cells for vaccine purposes and in-depth knowledge of working under industrial and cGMP quality requirements.
